Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...

Novartis said it is investing more than $40 million in the Carlsbad facility, which will be approximately 10,000 square feet. The company also said it will help create more than 30 local jobs. New ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali. The Swiss pharmaceutical ...

I was at Novartis headquarters in Basel yesterday ... For Spark, the deal means it won’t have to invest in building up dedicated sales and marketing teams for the therapy outside the US ...

Oct 16 (Reuters) - Novartis (NOVN.S), opens new tab has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by blocking regulators from ...

LONDON — Novartis on Tuesday increased its earnings guidance for the third time this year, boosted by strong sales of its leading drugs. The company said it anticipates full-year operating ...

The European Broadcasting Union (EBU) is delighted to announce Novartis as an ‘Official Partner’ for the 69th Eurovision Song Contest when it’s hosted in their hometown in Basel, Switzerland, next May ...

European markets closed lower Tuesday as traders in the region continued to digest the latest slew of earnings reports.

Exactly three years after an initial FDA green light for the third-line treatment of leukemia, Novartis’ Scemblix has won an accelerated approval to treat newly diagnosed patients. Tuesday ...

Novartis has terminated a phase 2 trial of its SMURF1 inhibitor LTP001 in idiopathic pulmonary fibrosis (IPF) but will continue to advance the candidate in another indication. The Swiss drugmaker ...

Truist highlights Novartis' strong balance sheet, which enables further bolt-on deals and share buybacks. Recent transactions primarily involve deals in the sub-$1 billion range, along with a few ...